Abstract
Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described.
Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS.
Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects.
Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.
Keywords: Interferon beta-1a, multiple sclerosis, regulatory T-cells, myelin, sheath, CNS, Treg cells.
CNS & Neurological Disorders - Drug Targets
Title:Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a
Volume: 17 Issue: 2
Author(s): Mohsen Ebrahimimonfared, Ali Ganji, Sara Zahedi, Parisa Nourbakhsh, Keyvan Ghasami and Ghasem Mosayebi*
Affiliation:
- Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak,Iran
Keywords: Interferon beta-1a, multiple sclerosis, regulatory T-cells, myelin, sheath, CNS, Treg cells.
Abstract: Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described.
Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS.
Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects.
Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.
Export Options
About this article
Cite this article as:
Ebrahimimonfared Mohsen , Ganji Ali , Zahedi Sara, Nourbakhsh Parisa , Ghasami Keyvan and Mosayebi Ghasem *, Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a, CNS & Neurological Disorders - Drug Targets 2018; 17 (2) . https://dx.doi.org/10.2174/1871527317666180327122435
DOI https://dx.doi.org/10.2174/1871527317666180327122435 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into the Pathogenesis of Type 1 Diabetes A Hint for Novel Immunospecific Therapies
Current Molecular Medicine Preface [Hot Topic: Transcription Factors as Targets of Novel Therapeutic Approaches of Autoimmune Diseases (Executive Editor: Gunther Ne)]
Current Pharmaceutical Design The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Molecular Mimicry in Autoimmune Neurological Disease after Viral Infection
Current Medicinal Chemistry Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis
Current Signal Transduction Therapy Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Natural Cures for Type 1 Diabetes: A Review of Phytochemicals, Biological Actions, and Clinical Potential
Current Medicinal Chemistry Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy Novel Molecular Targets for Systemic Lupus Erythematosus
Current Drug Targets Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy
Current Pharmaceutical Design Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Immune Deviation Strategies in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy